Novartis adds 100 jobs at Lek site in Slovenia as it muscles up on biosimilars

Eric Palmer

was the first drugmaker to get a biosimilar approved in the U.S. and has set itself up to be a major player in the growth of the biologic copies. That is going to require more development muscle, and so it has expanded its Lek subsidiary in , adding 100 in the process.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS